Clinical Lipidology. A Companion to BRAUNWALD's Heart Disease

SECTION I INTRODUCTION/BASIC MECHANISMS

1 Overview of Lipids and Atherosclerosis

 

SECTION II RISK ASSESSMENT

2 Overview of Risk Assessment

3 Measurement of Low- Density Lipoprotein Cholesterol, Non-High- Density Lipoprotein  Cholesterol, Apolipoprotein B, and Low- Density Lipoprotein Particle Concentration

4 Triglycerides, Triglyceride- Rich Lipoproteins, and High- Density Lipoprotein in Coronary Heart Disease Risk Assessment

5 Lipoprotein(a) in Cardiovascular Risk Assessment

6 Clinical Evaluation for Genetic Testing and Secondary Causes of Dyslipidemia

7 Polygenic Risk Scores

8 High- Sensitivity C- Reactive Protein

9 Emerging Assays for Risk Assessment

10 Imaging Atherosclerosis for Risk Stratifi cation: Cardiac Computed Tomography and Carotid Ultrasound

 

SECTION III THERAPY

11 Overview of General Approach to Management of Dyslipidemias

12 Treatment Guidelines Overview: American Heart Association/American College of Cardiology/Multisociety Guideline and Updates

13 Treatment Guidelines Overview: European Society of Cardiology/European Atherosclerosis Society Guidelines

14 Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease

15 Updated Clinical Guide to Exercise and Lipids

16 Obesity, Lipids, and Cardiovascular Disease

17 Statins

18 Cholesterol Absorption Inhibitors

19 Omega- 3 Fatty Acids

20 Proprotein Convertase Subtilisin/Kexin Type

9 Inhibition

21 Inclisiran

22 Bempedoic Acid

23 Pemafi brate: A New Selective Peroxisome Proliferator-Activated Receptor- Modulator for Hypertriglyceridemia Management

24 Anti- inflammatory Therapy for Cardiovascular Disease

25 Nutraceuticals and Functional Foods for Cholesterol Reduction

 

SECTION IV NEW AND EVOLVING THERAPEUTIC TARGETS AND PLATFORMS

26 Evolving Therapeutic Targets: Lipoprotein(a)

27 Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias

28 Evolving Therapeutic Targets: Apolipoprotein C- III

29 Evolving Therapeutic Targets: Cholesteryl Ester Transfer Protein Inhibition

30 Gene Therapy and Therapeutic Genome Editing in Liver for Lipid Disorders

 

SECTION V SPECIAL PATIENT POPULATIONS

31 Special Patient Populations: Diabetes and Metabolic Syndrome

32 Special Patient Populations: Women and Older Adults

33 Special Patient Populations: Children and Adolescents

34 Special Patient Populations: Familial Hypercholesterolemia and Other Severe Hypercholesterolemias

35 Special Patient Populations: Treatment of Familial Chylomicronemia Syndrome and Sustained Chylomicronemia

36 Special Patient Populations: Acute Coronary Syndromes

37 Special Patient Populations: Transplant Recipients

38 Special Populations: Chronic Kidney Disease

39 Special Patient Populations: Lipid Abnormalities in High- Risk Racial/Ethnic Groups

40 Persons With Human Immunodeficiency Virus

Part of the renowned Braunwald family of references, Clinical Lipidology: A Companion to Braunwald's Heart Disease provides today's clinicians with clear, authoritative guidance on the therapeutic management of patients with high cholesterol levels and other atherogenic lipid disorders. An invaluable resource for cardiologists, lipidologists, endocrinologists, and internal medicine physicians, this one-stop reference covers everything from basic science and the pathogenesis of atherothrombotic disease to risk assessment and the latest therapy options. Now fully updated from cover to cover, the 3rd Edition offers unparalleled coverage of lipidology in an accessible and user-friendly manner. Thoroughly covers the assessment, diagnosis, and treatment of patients with elevated levels of lipids and lipoproteins, including all the latest research-based recommendations, therapeutic breakthroughs, and related clinical advances. Presents the latest data on clinical guidelines, risk assessments, and established and emerging pharmacologic and nonpharmacologic therapies-all from internationally recognized experts in the field. Features condensed, streamlined content that focuses on clinical applications and applying concepts to the practice setting. Chapters have now been completely reorganized into sections on risk assessment; therapy; new and evolving therapeutic targets and platforms; and special populations. Includes new chapters on Polygenic Risk Scores; Inclisiran; Bempedoic Acid; Selective Peroxisome Proliferator-Activated Receptor-a Modulator: Pemafibrate; Evolving Therapeutic Targets: Lp(a), ANGPTL3, and ApoC-III; New Therapeutic Platforms: Gene Therapy and Genome Editing; and more. Contains new or expanded content on inflammation; genetic testing; troponins for risk assessment; statins and role of bile acid sequestrants, niacin, and fibrates; mAbs; CANTOS and CIRT; colchicine; IL-6; and cellular, molecular, and genetic therapy. Provides treatment algorithms throughout, as well as case vignettes that highlight the most common clinical questions in each chapter. Incorporates the latest guidelines from the AHA, ACC, ESC, and EAS, as well as future directions for ongoing research and emerging applications. Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.